Navigation Links
Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis

sing patients to lung infections, which continually damage their lungs. Pulmonary infection with Gram-negative bacteria, particularly pulmonary P. aeruginosa, represents the single greatest cause of morbidity and mortality among CF patients. Currently there is no known cure for CF, and the goal of CF therapy is to control symptoms and prevent further lung damage.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including statements related to Gilead's ability to obtain data from AIR-CF1 and submit an NDA for aztreonam lysine for inhalation for the treatment of CF to the U.S. FDA as currently planned. For example, the safety and efficacy data from additional clinical studies may not warrant further development of this compound and initiating and completing clinical trials may take longer or cost more than expected. In addition, future discussions with the FDA may impact the amount of data needed and timelines for review, which may differ materially from Gilead's current projections. Further, the U.S. FDA may not approve aztreonam lysine for inhalation for the treatment of CF in the United States, and any marketing approval, if granted, may have significant limitations on its use. These risks, uncertainties and other factors could cause actual results to differ materially fr
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:5/22/2015)... , May 22, 2015 The ... in 2014 and is estimated to reach $90.7 million by ... Browse through the TOC of North America Dental ... with the help of various tables and figures. ... 10% customization on this report.   Dental ...
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, Inc. ... tissue protection, repair and regeneration, today announced that ... scheduled to present a corporate overview at two upcoming ... at the SeeThruEquity 4 th Annual Microcap Conference ... York City at 11:00 am EDT.  A ...
(Date:5/22/2015)...  The U.S. Food and Drug Administration,s (FDA) ... biosimilar product approved in the United ... the contract manufacturing organization (CMO) industry, according to ... to the production of small-molecular drugs and lacks ... healthcare market research publisher,s report, Biopharmaceutical and ...
Breaking Medicine Technology:North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... N.Y. Feb. 7, 2011 BioSpecifics Technologies Corp. (Nasdaq: ... biopharmaceutical company developing first in class collagenase-based products, today ... Rights Agreement (the "Rights Agreement"), adopted May 14, 2002 ... The Amendment increases the ownership threshold for determining ...
... start-up, UrgentRx , today announced the launch of ... credit card-sized packets, including UrgentRx Aspirin to Go ... first aid.  February is the American Heart Association,s ... UrgentRx Aspirin to Go timely as research supports the ...
Cached Medicine Technology:UrgentRx Launches Line of Innovative and Portable, Fast-Acting Medications Across Colorado 2UrgentRx Launches Line of Innovative and Portable, Fast-Acting Medications Across Colorado 3
(Date:5/22/2015)... Washington, DC (PRWEB) May 22, 2015 ... Howard University Hospital’s world-renowned surgical oncologist, Dr. LaSalle D. ... celebration. , The luncheon began after Grand Rounds in ... Delores Leffall, waited anxiously outside the auditorium, trying to ... hear him, but if he sees me, he’ll know ...
(Date:5/22/2015)... May 22, 2015 Carnegie Science ... today announced a new partnership to develop BodyTech, a ... region. The initiative includes a new exhibit at the ... demonstration theater, and a new traveling science show, Anatomy ... of 2015. , Designed to explore a wide ...
(Date:5/22/2015)... May 22, 2015 Coordinating care ... difficult process. Historically providers have not been reimbursed ... Starting in 2015, Medicare has paved the way ... Thanks to the launch of Oculus Health ... health systems using the platform will now be ...
(Date:5/22/2015)... Memorial Day weekend is typically considered the beginning ... some tips to help promote safe travel. , According to ... traffic fatalities this Memorial Day weekend. Amica is sharing the ... Association: , , Always wear a ... seatbelt, whether they’re driving or riding along as a passenger. ...
(Date:5/22/2015)... According to a new Aegis Living Study ... as likely to worry about what will happen to their ... Boomers, 69% Silent Generation), which may help explain why nearly ... aging, particularly Millennials (47%), Gen X’ers (51%), and Boomers (43%). ... 2015 among more than 2,000 U.S. adults ages 18+. ...
Breaking Medicine News(10 mins):Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3
... Hopkins University School of Medicine had said that implants inside ... people can be equally effective for all, irrespective of the ... ,There is growing evidence that the amount of hearing ... patient’s ability to interpret speech using an implant, said the ...
... to as meconium aspiration) occurs when a newborn inhales ... and delivery. ,Meconium is the material that ... formed from ingested amniotic fluid and dead intestinal cells.// ... to the lung when the infant takes its first ...
... remains, may be at the root of bovine spongiform ... the latest issue of The Lancet had forwarded this ... case or cases of BSE is currently unknown. Sheep ... (TSE) that arose spontaneously has long been considered as ...
... treatment of AIDS/HIV infection that has been haunting the world. ... a puzzle to be tackled effectively. Approximately five percent of ... AIDS, or do so very slowly.// ,Past research ... in white blood cells called APOBEC-3G (A3G), and the new ...
... continues to claim victims in India's most populous state ... have died since the disease broke out a month ... Thursday visited Gorakhpur, where a nodal treatment centre was ... from neighbouring districts, and assured all possible help from ...
... the family at home can effectively encourager the ... for children suffering from diseases. ,Researchers from ... counseling could lead to healthier eating habits among ... // ,Genetic predisposition and unhealthy behaviors ...
Cached Medicine News:Health News:Mad Cow Disease Has Roots Traceable To Man 2Health News:Study holds promise for new way to fight HIV 2
... Are You Aware of the High ... the Cardiovascular Disease Patient Population?, , As ... ,Obstructive Sleep Apnea (OSA), the most common ... million people in the United States. ...
... Type 300 ,Oblique 45, ,Type 330 ... illumination by setting the illumination between ... be ideal for use in ophthalmology ... other conventional compact microscope can; an ...
... MedCath Diagnostics currently maintains a large number ... vascular labs in its rental fleet. The ... several months to several years. The Cath ... add capacity while replacing or upgrading existing ...
... This is one of our highly featured models. ... can select a target using the mouse to have ... machine that will allow the unit to photograph a ... model is that after you have taken the picture ...
Medicine Products: